Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study.

Archive ouverte

Loke, Justin | Labopin, Myriam | Craddock, Charles | Socié, Gérard | Gedde-Dahl, Tobias | Blaise, Didier | Forcade, Edouard | Salmenniemi, Urpu | Huynh, Anne | Versluis, Jurjen | Yakoub-Agha, Ibrahim | Labussière-Wallet, Hélène | Maertens, Johan | Passweg, Jakob | Bulabois, Claude Eric | Gabellier, Ludovic | Mielke, Stephan | Castilla-Llorente, Cristina | Deconinck, Eric | Brissot, Eolia | Nagler, Arnon | Ciceri, Fabio | Mohty, Mohamad

Edité par CCSD -

International audience. IntroductionFor the majority of patients with acute myeloid leukemia (AML) an allogeneic stem cell transplant (SCT) in first complete remission (CR) is preferred. However, whether the number of courses required to achieve CR has a prognostic impact is unclear. It is unknown which factors remain important in patients requiring more than one course of induction to attain remission.MethodsThis Acute Leukaemia Working Party study from the European Society for Blood and Marrow Transplantation identified adults who received an allograft in first CR from either a fully matched sibling or 10/10 or 9/10 human leucocyte antigen (HLA)-matched unrelated donor (HLA-A, HLA-B, HLA-C, HLA-DR, or HLA-DQ). Univariate and multivariate analyses were undertaken to identify the prognostic impact of one or two courses of induction to attain CR.ResultsA total of 4995 patients were included with 3839 (77%) patients attaining a CR following one course of induction chemotherapy (IND1), and 1116 patients requiring two courses (IND2) to attain CR. IND2 as compared to IND1 was a poor prognostic factor in a univariate analysis and remained so in a multivariate Cox model, resulting in an increased hazard ratio of relapse (1.38; 95% confidence interval [CI], 1.16–1.64; p = .0003) and of death (1.27; 95% CI, 1.09–1.47; p = .002). Adverse prognostic factors in a multivariate analysis of the outcomes of patients requiring IND2 included age, FLT3-ITD, adverse cytogenetics, and performance status. Pretransplant measurable residual disease retained a prognostic impact regardless of IND1 or IND2.ConclusionInitial response to chemotherapy as determined by number of courses to attain CR, retained prognostic relevance even following SCT in CR.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion